Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S FEXOFENADINE HYDROCHLORIDE HIVES versus CLISTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S FEXOFENADINE HYDROCHLORIDE HIVES versus CLISTIN.
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES vs CLISTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a peripheral H1-receptor antagonist that selectively inhibits histamine-mediated effects on H1 receptors, reducing allergic symptoms. It does not penetrate the blood-brain barrier significantly, minimizing sedation.
Clistin (histamine-1 receptor antagonist) competitively blocks histamine at H1 receptor sites, inhibiting vasodilation, increased capillary permeability, and bronchoconstriction. It also has anticholinergic and sedative properties.
Adults and children 12 years and older: 180 mg orally once daily or 60 mg orally twice daily.
4 mg orally every 4-6 hours as needed; maximum 24 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 14.4 hours (range 11–15 hours) in healthy adults. This supports once-daily dosing. Half-life may be prolonged in patients with renal impairment (up to 19 hours).
Terminal elimination half-life is approximately 8-12 hours in healthy adults. In patients with renal impairment, half-life may be prolonged, requiring dose adjustment.
Fexofenadine is primarily excreted unchanged in feces (approximately 80%) via biliary elimination, with minimal renal excretion (approximately 11%). It is not metabolized by the liver.
Primarily renal excretion (approximately 85-90% as unchanged drug and metabolites). Biliary/fecal elimination accounts for the remainder (10-15%).
Category A/B
Category C
Antihistamine
Antihistamine